Compare Lamb Weston Holdings Inc (LW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.16B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LW | TVTX | |
|---|---|---|
Market Cap | $7.16B | $4.88B |
Volume | 2,766,229 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $67.52 |
52-Week Low | $38.48 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $10.95B | $5.01B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.02, up 5.66% today, near the consensus price target of $53.71. The stock shows bullish technical signals with strong moving averages and recent earnings beats. Revenue reached $6.45B in 2025, though net income margin compressed to 3.85%. The company maintains a solid balance sheet with $70.70M cash and ongoing dividend payments of $0.38 per share.
Outlook remains mixed; analyst consensus leans Hold (63%) with potential upside to $58.00. Key risks include margin pressure from high debt and volatile earnings. Positive sentiment from cost-saving initiatives supports recovery, but investor confidence hinges on sustained profitability improvements amid competitive pressures.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
